Is Aytu BioPharma, Inc. (AYTU) a Buy, Sell, or Hold?
Aytu BioPharma, Inc.
NASDAQ:AYTU
$2.21 USD
$0.01 (0.45%)
- Volume
- 351
- Average Volume
- 37.27K
- Market Capitalization
- $17.9M
- P/E Ratio
- -0.52
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $3.07
- Year Low
- $1.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.12
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joshua R. Disbrow |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | AYTU |
| CUSIP | 054754858 |
| CIK | 0001385818 |
| Web | https://aytubio.com |
| Phone | 720 437 6580 |
| Currency | USD |
| Employees | 83 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.65 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.12 |
| Quick Ratio | 1.00 |
| Cash Ratio | 0.45 |
Sales & Book Value
| Annual Sales | $66.38M |
| Price / Sales | 0.32 |
| Cash Flow | 0.16 |
| Price / Cash Flow | 10.89 |
| Price / Book | 0.66 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.16 |
| Trailing P/E Ratio | -0.52 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-13.56M |
| Net Margin | -60.17% |
| Pretax Margin | -59.49% |
| Return on Equity | -148.91% |
| Return on Assets | -30.49% |
Financials Score
| AltmanZ Score | -4.56 |
| Piotroski Score | 3.00 |
| Working Capital | 7.35M |
| Total Assets | 111.69M |
| Ebit | -31.43M |
| Market Cap | 18.1M |
| Total Liabilities | 76.55M |
Poll Results
About Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Ot ... her products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
2026-06-01 16:15:00
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-18 16:05:00
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:15 a.m.
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
2026-05-13 21:30:44
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
2026-05-13 18:36:16
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.2 per share a year ago.
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
2026-05-13 16:05:00
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 million Adjusted EBITDA1 of $(2.8) million, which includes EXXUA ™ (gepirone) extended-release tablets ( " EXXUA " ) launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ( " MDD " ) market $26.7 million cash balance at March 31, 2026 Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / May 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 third quarter.
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
2026-05-06 16:05:00
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m.
Frequently Asked Questions
-
What is the current Aytu BioPharma, Inc. (AYTU) stock price?
-
Aytu BioPharma, Inc.(NASDAQ:AYTU) stock price is $2.21 in the last trading session. During the trading session, AYTU stock reached the peak price of $3.07 while $1.65 was the lowest point it dropped to. The percentage change in AYTU stock occurred in the recent session was 0.45% while the dollar amount for the price change in AYTU stock was $0.01.
-
AYTU's industry and sector of operation?
-
The NASDAQ listed AYTU is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of AYTU?
-
Gerwin Westfield | Senior Vice President of Scientific Affairs
Margaret Cabano | Vice President of Operations
Greg Pyszczymuka | Chief Commercial Officer
Jarrett T. Disbrow | Chief Business Officer
Joshua R. Disbrow | Chief Executive Officer & Director -
How many employees does AYTU have?
-
Number of AYTU employees currently stands at 83. AYTU operates from 373 Inverness Parkway, Englewood, CO 80112, US.
-
Link for AYTU official website?
-
Official Website of AYTU is: https://aytubio.com
-
How do I contact AYTU?
-
AYTU could be contacted at phone #720 437 6580 and can also be accessed through its website. AYTU operates from 373 Inverness Parkway, Englewood, CO 80112, US.
-
How many shares of AYTU are traded daily?
-
The average number of AYTU shares traded daily for last 3 months was 37.27K.
-
What is the market cap of AYTU currently?
-
The market value of AYTU currently stands at $17.9M with its latest stock price at $2.21